Nigel Crockett Ph.D.
Net Worth
Last updated:
What is Nigel Crockett Ph.D. net worth?
The estimated net worth of Dr. Nigel Crockett Ph.D. is at least $5,173,077 as of 3 Oct 2024. He owns shares worth $328,086 as insider, has earned $2,572,511 from insider trading and has received compensation worth at least $2,272,480 in Bicycle Therapeutics plc.
What is the salary of Nigel Crockett Ph.D.?
Dr. Nigel Crockett Ph.D. salary is $568,120 per year as Chief Bus. Officer in Bicycle Therapeutics plc.
How old is Nigel Crockett Ph.D.?
Dr. Nigel Crockett Ph.D. is 60 years old, born in 1965.
What stocks does Nigel Crockett Ph.D. currently own?
As insider, Dr. Nigel Crockett Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Bicycle Therapeutics plc (BCYC) | Chief Bus. Officer | 45,822 | $7.16 | $328,086 |
What does Bicycle Therapeutics plc do?
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Nigel Crockett Ph.D. insider trading
Bicycle Therapeutics plc
Dr. Nigel Crockett Ph.D. has made 12 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 972 units of BCYC stock worth $21,637 on 3 Oct 2024.
The largest trade he's ever made was exercising 72,701 units of BCYC stock on 13 Jul 2021. As of 3 Oct 2024 he still owns at least 45,822 units of BCYC stock.
Bicycle Therapeutics key executives
Bicycle Therapeutics plc executives and other stock owners filed with the SEC:
- Dr. Dominic Smethurst M.A., M.D. (51) Chief Medical Officer
- Dr. Kevin Lee M.B.A., Ph.D. (56) Chief Executive Officer & Executive Director
- Dr. Michael Skynner Ph.D., B.sc. Ph.d. (55) Chief Operating Officer
- Dr. Nigel Crockett Ph.D. (60) Chief Bus. Officer
- Mr. Lee H. Kalowski (44) Pres & Chief Financial Officer
- Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE (74) Co-Founder, Non-Executive Director & Member of Scientific Advisory Board